References
- Moreland KW, Shiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheuma-toid arthritis. A randomised, controlled trial. Ann Intern Med 1999;130:478.
- Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombi-nant human tumor necrosis factor: Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253.
- Bathon JM, Martin RW, Fleishmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586–93.
- Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004;363:675–81.
- Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agents. N Engl J Med 2001;345:1098–104.
- Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148–55.
- WHO report Global tuberculosis control-surveillance, planning, financing. hap://www.who.int/tb/publications/global_report/en/
- Report from the Ministry of Health, Labor and Welfare Japan (in Japanese). hap://www.jata.or.jp/rit/rj/data_tp.html
- Miyasaka N, Takeuchi T, Eguchi K: Proposed Japanese guidelines for the use of infliximab for rheumatoid arthritis. Mod Ftheumatol 2005;15:4–8.
- American College of Ftheumatology-Hotline: 1. http://www. rheumatology.org/publications/hotline/0303tnfLasp
- Safety Update TNF-a blocking agents: 1. http://www.fda.gov/ ohrms/dockets/ac/03/transcripts/3930T1.htm
- Van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FN, von Blomberg BM, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology, 1996;47:1531.
- Genovese MC, Bathon JM, Fleischmann RM, Moreland LW, Martin RW, Whitmore JB, et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Ftheumatol 2005;32: 1232–42.
- Miyasaka N. Research report of "Development of Guidelines for the Treatment of Rheumatoid Arthritis with New Biological Products and Research on Their Validation" supported by a Grant-in-Aid for Scientific Research (Prevention and Research of Immunologic and Allergic Diseases) from the Ministry of Health, Labour and Welfare, Japan in 2004; in press.
- Study Group of the Ministry of Health, Labour and Welfare. Therapeutic manual of rheumatoid arthritis (revised). Diagnostic manual and evidence-based treatment guidelines. Japan Rheuma-tism Foundation; 2004.
- Sakai F, Noma S, Kurihara Y, Yamada H, Azuma A, Kudoh S, et al. Leflunomide-related lung injury in patients with rheumatoid arthritis: imaging features. Mod Ftheumatol 2005; 15:73–9.
- Ogawa J, Harigai M, Nagasaka N, Nakamura T, Miyasaka N, et al. Prediction of and prophylaxis against pneumocystic pneumonia in patients with connective tissue diseases undergoing medium-or high-dose corticosteroid therapy. Mod Rheumatol 2005;15: 91–6.
- Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, De Vries T, et al. One-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis. Results of a multicenter, rand-omized, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50: 353–63.